Vaccine therapy for malignant glioma with costimulatory signal genemodified syngenic glioma cells

1998 Fiscal Year Final Research Report Summary

• Project/Area Number: 08671597
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Cerebral neurosurgery
• Research Institution: UNIVERSITY OF THE RYUKYUS
• Principal Investigator: MIYAGI Koichi Univ.of Ryukyus, School of Med., Associate Prof., 医学部, 助教授 (60102274)
• Co-Investigator(Kenkyū-buntansha): TADANO Masayuki Univ.of Ryukyus, School of Med., Associate Prof., 医学部, 助教授 (80179712) ; MAKINO Yoshihiro Univ.of Ryukyus, School of Med., Associate Prof., 医学部, 助教授 (60039930) ; YOSHII Yoshihiko Univ.of Ryukyus, School of Med., Prof., 医学部, 教授 (50110507)
• Project Period (FY): 1996 – 1998
• Keywords: B7 / costimulatory signal / gene therapy / glioblastoma / glioma / tumor vaccine

Research Abstract

In order to substantiate the usefulness of genetic modification of glioma cell to express the B7 gene as tumor vaccine against malignant glioma, we did in vivo study. Cells used for this study were T9 (Fischer rat origin) and C6 glioma (Wister rat origin) cell. pLXEN-B7-1 plasmid were cotransfected into T9 and C6 glioma cell by Chen-Okayama method, and B7(+)T9 glioma cell clone, B7(-t-)C6 glioma cell clone were elicited. 5x106 cells of T9, B7(+)T9, C6, B7(+)C6 cells were injected subcutaneously into the shaved flank of syngenic rat and observed for 3 weeks. Weights of transplanted tumor were as follows, T9 glioma ; 7.02gm. B7(+)T9 glioma ; 1.9gm, T9 glioma with counterpart B7(+) cell ; 6.3gm. Concerning C6 glioma, C6 glioma ; 6.09gm, B7(+)C6 glioma ; 3.6gm, C6 glioma with counterpart B7(+) cell ; 16.8gm(including necrotic cystic fluid). Pathological examination of B7(+) glioma reveals lot of lymphocyte infiltration. B7(+) glioma cells were immunogenic, however transplantation of B7(+) glioma fail to elicit antitumor immunity against contralateral wild type glioma.